BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31197523)

  • 1. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
    Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
    World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies.
    Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
    Urology; 2020 Mar; 137():126-132. PubMed ID: 31899229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
    Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
    Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study.
    Ploussard G; Beauval JB; Lesourd M; Manceau C; Almeras C; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
    World J Urol; 2020 Jul; 38(7):1735-1740. PubMed ID: 31612251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.
    Radtke JP; Kuru TH; Bonekamp D; Freitag MT; Wolf MB; Alt CD; Hatiboglu G; Boxler S; Pahernik S; Roth W; Roethke MC; Schlemmer HP; Hohenfellner M; Hadaschik BA
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):283-91. PubMed ID: 27184812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
    BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
    Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
    Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance.
    Shapiro DD; Gregg JR; Lim AH; Nogueras-González GM; Choi H; Kang HC; Inguillo IA; Chapin BF; Davis JW; Ward JF
    BJU Int; 2021 Mar; 127(3):340-348. PubMed ID: 32357283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
    Kesch C; Pantea V; Soeterik T; Marquis A; la Bombarda G; Morlacco A; Barletta F; Radtke JP; Darr C; Preisser F; Zattoni F; Marra G; van den Bergh RCN; Hadaschik B; Gandaglia G;
    World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies.
    Manceau C; Fromont-Hankard G; Beauval JB; Lesourd M; Almeras C; Bajeot AS; Gautier JR; Soulié M; Loison G; Salin A; Tollon C; Malavaud B; Roumiguié M; Ploussard G
    World J Urol; 2021 Sep; 39(9):3315-3321. PubMed ID: 33609168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
    Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Moschini M; Zamboni S; Rakauskas A; Tian Z; Karakiewicz PI; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
    Eur Urol; 2020 Jun; 77(6):733-741. PubMed ID: 31547938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
    Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.
    Diamand R; Oderda M; Al Hajj Obeid W; Albisinni S; Van Velthoven R; Fasolis G; Simone G; Ferriero M; Roche JB; Piechaud T; Pastore A; Carbone A; Fiard G; Descotes JL; Marra G; Gontero P; Altobelli E; Papalia R; Kumar P; Eldred-Evans D; Giacobbe A; Muto G; Lacetera V; Beatrici V; Roumeguere T; Peltier A
    World J Urol; 2019 Oct; 37(10):2109-2117. PubMed ID: 30652213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study.
    Diamand R; Hollans M; Lefebvre Y; Sirtaine N; Limani K; Hawaux E; Abou Zahr R; Mattlet A; Albisinni S; Roumeguère T; Peltier A
    Urol Oncol; 2022 May; 40(5):192.e11-192.e17. PubMed ID: 35236622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
    He Y; Shen Q; Fu W; Wang H; Song G
    Prostate; 2022 Aug; 82(11):1125-1132. PubMed ID: 35538399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
    Ma TM; Tosoian JJ; Schaeffer EM; Landis P; Wolf S; Macura KJ; Epstein JI; Mamawala M; Carter HB
    Eur Urol; 2017 Feb; 71(2):174-180. PubMed ID: 27236496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
    Maxeiner A; Kittner B; Blobel C; Wiemer L; Hofbauer SL; Fischer T; Asbach P; Haas M; Penzkofer T; Fuller F; Miller K; Cash H
    BJU Int; 2018 Aug; 122(2):211-218. PubMed ID: 29569320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?
    Mazzone E; Stabile A; Sorce G; Pellegrino F; Barletta F; Motterle G; Scuderi S; Cirulli GO; Cucchiara V; Brembilla G; Esposito A; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Karnes RJ; Guccini I; Briganti A
    Urol Oncol; 2021 Nov; 39(11):784.e1-784.e9. PubMed ID: 33865687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients.
    Bloom JB; Daneshvar MA; Lebastchi AH; Ahdoot M; Gold SA; Hale G; Mehralivand S; Sanford T; Valera V; Wood BJ; Choyke PL; Merino MJ; Turkbey B; Parnes HL; Pinto PA
    Urol Oncol; 2021 Oct; 39(10):729.e1-729.e6. PubMed ID: 33736975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance.
    Tran GN; Leapman MS; Nguyen HG; Cowan JE; Shinohara K; Westphalen AC; Carroll PR
    Eur Urol; 2017 Aug; 72(2):275-281. PubMed ID: 27595378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.